Visit EAACI Digital Congress 2020 with us!

EAACI Digital Congress 2020 is a new milestone in the long story of Allergy Congresses and we couldn't miss this great event! It is our pleasure to invite you to visit the first Bilastine Digital Booth, carefully thought to provide you with relevant scientific content and let you know more about Bilastine, the newest antihistamine worldwide!   Aditionally, we would like to invite you to participate in a Real World Clinical Case Challenge. We count on your visit to contribute to a great EAACI event. Visit EAACI.org Or join us at BILASTINA.COM

Copyright © 2020 Faes Farma, All rights reserved. ADVERTENCIA LEGAL Este correo electrónico y, en su caso, cualquier fichero anexo al mismo, contiene información de carácter confidencial exclusivamente dirigida a su destinatario. Queda prohibida su divulgación, copia o distribución a terceros sin la previa autorización escrita de Faes Farma, S.A. En el caso de haber recibido este correo electrónico por error, se ruega notifíquese inmediatamente esta circunstancia mediante reenvío a la dirección electrónica del remitente. De conformidad con lo establecido en la LOPD, Faes Farma, S.A. garantiza la adopción de las medidas necesarias para asegurar el tratamiento confidencial de los datos de carácter personal y el cumplimiento de los dispuesto en el Reglamento General de Protección de Datos (RGPD). Si no desea recibir nuestras comunicaciones puede enviarnos un mensaje de correo a nuestro buzón de correo electrónico webmaster@faesfarma.com o pulse aquí. This email and any attachements to it contains confidential information exclusively intended for the recipients. Any divulgation, copy or distribution to third parties is prohibited without the written permission of Faes Farma, S.A. If you have received this e-mail in error, please notify the sender immediately. In accordance with the Spanish Data Privacy Law (LOPD), Faes Farma, S.A. guarantees that it has adopted the necessary measures to ensure the confidential treatment of personal information and the compliance with the General Data Protection Regulation (GDPR).

Concordance for changes in allergic asthma domain variables after short-term corticosteroid therapy

Research article - Open Access

BMC Pulmonary Medicine

Philip E. Silkoff, Mark Sarno, Solomon Ssenyange, Vivek Balasubramanyam, Brian Awabdy & Ryan Leard

BMC Pulmonary Medicine volume 20, Article number: 139 (2020)

Abstract

Background

Asthma is a complex syndrome with multiple domains including symptoms, lung function, asthma control, and airway inflammation. A study of Fenom PRO™, a novel monitor for exhaled nitric oxide (FeNO), provided an opportunity to look at concordance/discordance (C/D) for changes in multiple asthma domains over a 2-week period after corticosteroid therapy.

Methods

Non-steroid-treated adults and children with uncontrolled asthma had asthma domain measures, (FeNO), forced expired volume in 1 s (FEV1), the 6-item Asthma Control Questionnaire scores (ACQ6), and daily asthma symptoms, assessed before and after a 2-week course of corticosteroids.

The pulmonary sequalae in discharged patients with COVID-19: a short-term observational study

Respiratory Research Research- Open Access
Dehan Liu, Wanshu Zhang, Feng Pan, Lin Li, Lian Yang, Dandan Zheng, Jiazheng Wang & Bo Liang Respiratory Research volume 21, Article number: 125 (2020)

• detail

Abstract

Background
A cluster of patients with coronavirus disease 2019 (COVID-19) pneumonia were discharged from hospitals in Wuhan, China. We aimed to determine the cumulative percentage of complete radiological resolution at each time point, to explore the relevant affecting factors, and to describe the chest CT findings at different time points after hospital discharge.

Methods

Patients with COVID-19 pneumonia confirmed by RT-PCR who were discharged consecutively from the hospital between 5 February 2020 and 10 March 2020 and who underwent serial chest CT scans on schedule were enrolled.

Sialylation of immunoglobulin E is a determinant of allergic pathogenicity

Kai-Ting C. Shade, 

Michelle E. Conroy, 

Nathaniel Washburn, 

Maya Kitaoka, 

Daniel J. Huynh, 

Emma Laprise, 

Sarita U. Patil, 

Wayne G. Shreffler & 

Robert M. Anthony 

Nature (2020)

• details

Abstract

Approximately one-third of the world’s population suffers from allergies1. Exposure to allergens crosslinks immunoglobulin E (IgE) antibodies that are bound to mast cells and basophils, triggering the release of inflammatory mediators, including histamine2. Although IgE is absolutely required for allergies, it is not understood why total and allergen-specific IgE concentrations do not reproducibly correlate with allergic disease3,4,5. It is well-established that glycosylation of IgG dictates its effector function and has disease-specific patterns. However, whether IgE glycans differ in disease states or affect biological activity is completely unknown6. Here we perform an unbiased examination of glycosylation patterns of total IgE from individuals with a peanut allergy and from non-atopic individuals without allergies.

COVID-19 & AIT: A Q&A with Prof. W. Canonica and A/Prof J.Rimmer

Quercetin with the potential effect on allergic diseases

• Review
• Open Access
• 
  

• Morteza Jafarinia, 
• Mahnaz Sadat Hosseini, 
• Neda kasiri, 
• Niloofar Fazel, 
• Farshid Fathi, 
• Mazdak Ganjalikhani Hakemi & 
• Nahid Eskandari 

Allergy, Asthma & Clinical Immunology volume 16, Article number: 36 (2020) Cite this article

• details

Abstract

Quercetin is a naturally occurring polyphenol flavonoid which is rich in antioxidants. It has anti-allergic functions that are known for inhibiting histamine production and pro-inflammatory mediators. Quercetin can regulate the Th1/Th2 stability, and decrease the antigen-specific IgE antibody releasing by B cells. Quercetin has a main role in anti-inflammatory and immunomodulatory function which makes it proper for the management of different diseases.

3 categories of SARCoV2 testing - Infographic

Spacers and Valved Holding Chambers—The Risk of Switching to Different Chambers

REVIEW AND FEATURE ARTICLE

VOLUME 8, ISSUE 5, P1569-1573, MAY 01, 2020

Federico Lavorini, MD, PhD Celeste Barreto, MD, Job F.M. van Boven, PhD, Will Carroll, MD, Joy Conway, PhD, Richard W. Costello, MD, Birthe Hellqvist Dahl, PhD, Richard P.N. Dekhuijzen, MD, Stephen Holmes, MD, Mark Levy, MD, Mathieu Molimard, MD, PhD, Nicholas Roche, MD, PhD, Miguel Román-Rodriguez, MD, Nicola Scichilone, MD, Jane Scullion, MSc, Omar S. Usmani, MD, PhD

Abstract

Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs);